10 Firms Shine Amid Wall Street’s Lackluster Trading

A lackluster trading persisted throughout Thursday, with Wall Street’s main indices ending the day with only marginal changes.

The Dow Jones Industrial Average dipped by 0.16 percent, while the S&P 500 shed 0.21 percent, and the Nasdaq Composite declined by 0.89 percent.

Meanwhile, 10 companies bucked an overall dull trading, having posted impressive gains. Let’s take a closer look at the top performers and explore the factors driving their exceptional results.

To come up with Thursday’s top gainers, we considered only the stocks with at least $2 billion in market capitalization and $5 million in daily trading volume.

A trader cheers on gains. Photo by Tima Miroshnichenko on Pexels

10. SoFi Technologies Inc. (NASDAQ:SOFI)

SoFi Technologies (SOFI) rose for a third day on Thursday, adding 5.09 percent to close at $16.3 apiece as investors took heart from news that it raised $525 million from a loan program with PGIM Fixed Income.

The transaction followed a $350 million investment from PGIM in May 2024 and builds on SoFi’s $3.9 billion in personal loan collateral sold in the third quarter of 2024 alone.

Edwin Wiches, managing director and co-head of securitized products at PGIM, said that SoFi’s personal loans represent an attractive opportunity for PGIM.

“We continue to expand our platform as an asset-based finance lender and source investments that provide compelling risk-adjusted returns for our clients with partners who put their customers first,” he said.

9. DexCom Inc. (NASDAQ:DXCM)

DexCom (DXCM), a company that manufactures and distributes continuous glucose monitoring systems for diabetes management, saw its shares rally by 5.52 percent on Thursday, ending the day at $84.84 each after earning an optimistic outlook from an analyst.

During the day, investment banking firm Baird upgraded its outlook for DexCom to “outperform” from “neutral,” citing progress in US sales and upcoming catalysts to buoy its business performance.

It also raised its price target for DexCom by 6 percent to $104 from $98 previously.

According to Baird, its outlook was based on projections of improved salesforce productivity and the potential for US growth to return to low-to-mid teens in the middle of the year.

DexCom also recently made earlier-than-expected progress on the G7 15-day sensor and its potential approval for hospital-based use.